First Patient Enrolled in SNR High Dose High Intensity Study with MindMaze Therapeutics
MindMaze Therapeutics Holding SA (SIX: MMTX), today announced that the SwissNeuroRehab Consortium (www.swissneurorehab.ch) has enrolled its first patient in the High-Dose, High-Intensity (HDHI) neurorehabilitation study – Advancing At-Home Reimbursement Strategy in Europe.
The study is a multicenter feasibility and implementation project evaluating whether HDHI neurorehabilitation can be delivered sustainably within a continuum-of-care framework. The study is powered by MindMaze’s precision neurotherapeutic platform (including MindMotionGO, Izar, and Companion). The study targets 300 minutes of active training per week, spanning a 4-6 week inpatient phase, an 8-12 week outpatient/home phase, and a follow-up at 15 months from inclusion.
Recruitment is active at Lausanne University Hospital (CHUV), Institution de Lavigny, Rehaklinik Valens, Swiss Rehabilitation Sàrl, Universitätsspital Zürich, and the Lake Lucerne Institute. The study is sponsored by the CHUV, funded within the Innosuisse FlagShip Program, under the project SwissNeuroRehab, and registered on ClinicalTrials.gov (NCT07427511).
“SwissNeuroRehab brings together Switzerland’s leading rehabilitation institutions to rigorously evaluate HDHI therapy along the continuum of care. This is precisely the evidence base payers and policymakers need,”
said Professor Andrea Serino, Coordinator of SwissNeuroRehab and Director of the Neurorehab Research Center, CHUV.
“The technology being validated in this study has the potential to fundamentally reshape post-stroke recovery, extending to home, at scale, and sustainably reimbursed,”
said Olivier Bill, MD, Principal Investigator, CHUV.
For recruitment details:
[SwissNeuroRehab HDHI Study Flyer]
More information is available here:
[MindMaze Therapeutics press release]
You May Also Like
